UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

Synthesis and biological activity of trans-(.+-.)-N-methyl-2-(3-pyridyl)-2-tetrahydrothiopyrancarbothioamide 1-oxide (RP 49356) and analogs: a new class of potassium channel opener

Journal of medicinal chemistry, 1992-10, Vol.35 (20), p.3613-3624

1992

Link zum Volltext

Verfügbarkeit prüfen

Syntheses and biological activities of potent potassium channel openers derived from (.+-.)-2-oxo-1-pyridin-3-yl-cyclohexanecarbothioic acid methylamide: new potassium channel openers

Journal of medicinal chemistry, 1993-05, Vol.36 (11), p.1604-1612

1993

Link zum Volltext

Verfügbarkeit prüfen

Acylthioxanthenes: agents which selectively reduce decerebrate rigidity in the cat

Journal of medicinal chemistry, 1980-06, Vol.23 (6), p.653-657

1980

Link zum Volltext

Verfügbarkeit prüfen

Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement

Journal of antimicrobial chemotherapy, 2012-05, Vol.67 (5), p.1053-1062

2012

Link zum Volltext

Verfügbarkeit prüfen

‘Carbon-Monoxide-Releasing Molecule-2 (CORM-2)’ Is a Misnomer: Ruthenium Toxicity, Not CO Release, Accounts for Its Antimicrobial Effects

Antioxidants, 2021-06, Vol.10 (6), p.915

2021

Link zum Volltext

Verfügbarkeit prüfen

Changing epidemiology of candidaemia in Australia

Journal of antimicrobial chemotherapy, 2017-04, Vol.72 (4), p.1103-1108

2017

Link zum Volltext

Verfügbarkeit prüfen

Corneal gene therapy

Journal of controlled release, 2007-12, Vol.124 (3), p.107-133

2007

Link zum Volltext

Verfügbarkeit prüfen

Statistical analysis of preclinical inter-species concordance of histopathological findings in the eTOX database

Regulatory toxicology and pharmacology, 2023-02, Vol.138, p.105308, Article 105308

2023

Link zum Volltext

Verfügbarkeit prüfen

Discovery of oral and inhaled PDE4 inhibitors

Bioorganic & medicinal chemistry letters, 2013-10, Vol.23 (20), p.5528-5532

2013

Link zum Volltext

Verfügbarkeit prüfen

A-887826 is a structurally novel, potent and voltage-dependent Na(v)1.8 sodium channel blocker that attenuates neuropathic tactile allodynia in rats

Neuropharmacology, 2010-09, Vol.59 (3), p.201-207

2010

Link zum Volltext

Verfügbarkeit prüfen

Discovery and biological evaluation of potent, selective, orally bioavailable, pyrazine-based blockers of the Na(v)1.8 sodium channel with efficacy in a model of neuropathic pain

Bioorganic & medicinal chemistry, 2010-11, Vol.18 (22), p.7816-7825

2010

Link zum Volltext

Verfügbarkeit prüfen

Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain

Bioorganic & medicinal chemistry, 2008-06, Vol.16 (12), p.6379-6386

2008

Link zum Volltext

Verfügbarkeit prüfen

Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives

Bioorganic & medicinal chemistry letters, 2010-11, Vol.20 (22), p.6812-6815

2010

Link zum Volltext

Verfügbarkeit prüfen

Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration

European journal of pharmacology, 2010-09, Vol.643 (2), p.274-281

2010

Link zum Volltext

Verfügbarkeit prüfen

Predictors for Glucose Change in Hypertensive Participants Following Short-term Treatment with Atenolol or Hydrochlorothiazide

Pharmacotherapy, 2014-11, Vol.34 (11), p.1132-1140

2014

Link zum Volltext

Verfügbarkeit prüfen

Closeout of the HALT-PKD trials

Contemporary clinical trials, 2015-09, Vol.44, p.48-55

2015

Link zum Volltext

Verfügbarkeit prüfen

Effects of early postnatal alcohol exposure on the developing retinogeniculate projections in C57BL/6 mice

Alcohol (Fayetteville, N.Y.), 2013-05, Vol.47 (3), p.173-179

2013

Link zum Volltext

Verfügbarkeit prüfen

SCH 206272: a potent, orally active tachykinin NK1, NK2, and NK3 receptor antagonist

European journal of pharmacology, 2002-08, Vol.450 (2), p.191-202

2002

Link zum Volltext

Verfügbarkeit prüfen

4-(Phenylsulfonyl)piperidines: Novel, Selective, and Bioavailable 5-HT2A Receptor Antagonists

Journal of medicinal chemistry, 2002-01, Vol.45 (2), p.492-503

2002

Link zum Volltext

Verfügbarkeit prüfen

Peripheral and central sites of action of GABA‐B agonists to inhibit the cough reflex in the cat and guinea pig

British journal of pharmacology, 1994-12, Vol.113 (4), p.1344-1348

1994

Link zum Volltext

Verfügbarkeit prüfen

Intravenous Ribavirin for Hantavirus Pulmonary Syndrome: Safety and Tolerance during 1 Year of Open-Label Experience

Antiviral therapy, 1999-01, Vol.4 (4), p.211-219

1999

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer

Investigational new drugs, 2005-12, Vol.23 (6), p.563-567

2005

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Performance and Learning Parity Between Campus-based and Web-based Medicinal Chemistry Courses

American journal of pharmaceutical education, 2005-01, Vol.69 (2), p.33

2005

Link zum Volltext

Verfügbarkeit prüfen

Second-Generation Benzodiazepine CCK-B Antagonists. Development of Subnanomolar Analogs with Selectivity and Water Solubility

Journal of medicinal chemistry, 1994-03, Vol.37 (6), p.722-724

1994

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 30

Suche als RSS-Feed

Aktive Filter

ThemaRetrospective Studies

Nur zeigenMit Volltextzugriff

ThemaPharmacology & Pharmacy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Synthesis and biological activity of trans-(.+-.)-N-methyl-2-(3-pyridyl)-2-tetrahydrothiopyrancarbothioamide 1-oxide (RP 49356) and analogs: a new class of potassium channel opener

Syntheses and biological activities of potent potassium channel openers derived from (.+-.)-2-oxo-1-pyridin-3-yl-cyclohexanecarbothioic acid methylamide: new potassium channel openers

Acylthioxanthenes: agents which selectively reduce decerebrate rigidity in the cat

Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement

‘Carbon-Monoxide-Releasing Molecule-2 (CORM-2)’ Is a Misnomer: Ruthenium Toxicity, Not CO Release, Accounts for Its Antimicrobial Effects

Changing epidemiology of candidaemia in Australia

Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1S,2S)‑2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic Acid (AZD9898) as a New Treatment for Asthma

Corneal gene therapy

Statistical analysis of preclinical inter-species concordance of histopathological findings in the eTOX database

Discovery of oral and inhaled PDE4 inhibitors

A-887826 is a structurally novel, potent and voltage-dependent Na(v)1.8 sodium channel blocker that attenuates neuropathic tactile allodynia in rats

Discovery and biological evaluation of potent, selective, orally bioavailable, pyrazine-based blockers of the Na(v)1.8 sodium channel with efficacy in a model of neuropathic pain

Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain

Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives

Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration

Predictors for Glucose Change in Hypertensive Participants Following Short-term Treatment with Atenolol or Hydrochlorothiazide

Closeout of the HALT-PKD trials

Effects of early postnatal alcohol exposure on the developing retinogeniculate projections in C57BL/6 mice

SCH 206272: a potent, orally active tachykinin NK1, NK2, and NK3 receptor antagonist

4-(Phenylsulfonyl)piperidines: Novel, Selective, and Bioavailable 5-HT2A Receptor Antagonists

Peripheral and central sites of action of GABA‐B agonists to inhibit the cough reflex in the cat and guinea pig

Intravenous Ribavirin for Hantavirus Pulmonary Syndrome: Safety and Tolerance during 1 Year of Open-Label Experience

Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer

Evaluation of Performance and Learning Parity Between Campus-based and Web-based Medicinal Chemistry Courses

Second-Generation Benzodiazepine CCK-B Antagonists. Development of Subnanomolar Analogs with Selectivity and Water Solubility

Aktive Filter

Suchergebnisse filtern